Medical science has achieved a remarkable milestone—gene therapies now offer potential cures for previously untreatable diseases. Yet a critical paradox threatens to undermine these breakthroughs: the healthcare system lacks the financial infrastructure to deliver them to patients.
According to health economist William Padula’s analysis, gene therapies costing up to $2 million per treatment have exposed fundamental weaknesses in how healthcare systems allocate resources. Traditional payment models evolved to manage recurring treatments and chronic disease management, not one-time curative interventions with unprecedented price tags.
Padula articulates the core challenge: “We do not lack cures. We lack the infrastructure to pay for and deliver them.” Healthcare organizations, payers, and policymakers must collaborate to develop innovative financing mechanisms that can bridge this critical gap and ensure equitable patient access to these life-saving treatments.
Read the full article on GMJ Newsroom.
Was this article helpful?
